Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna, Austria.
Influenza vaccines can be produced faster using a new insect cell-based technology than traditional egg-based processes, according to scientists in Vienna, Austria. The new technique involves using insect cells to create recombinant influenza virus-like particles (VLPs) that resemble virus particles, but lack the viral nucleic acid, which means they are not infectious.
"Recent outbreaks of influenza highlight the importance of a rapid and sufficient vaccine supply for pandemic and inter-pandemic strains," said Florian Krammer, co-author of the University of Natural Resources and Applied Life Science study in Vienna, in a press statement.
Traditional influenza vaccines are produced in embryonated chicken eggs and although they can be manufactured in sufficient quantities for seasonal influenza strains, the method may be insufficient in a pandemic situation because of limited egg supply.
Using the new insect cell-based method, the Austrian team took only 10 weeks to produce swine-origin pandemic H1N1 swine-flu influenza VLPs for immunological studies in mice. Conventional production methods, however, would take months. Using insect cells also overcomes some of the problems associated with egg-based methods, such as allergic reactions to egg proteins and biosafety issues.
"Our work demonstrates that recombinant influenza VLPs are a very fast, safe and efficient alternative to conventional influenza vaccines and represents a significant new approach for newly emerging influenza strains such as H1N1 or H5N1," said Krammer in the release.
The study appears in the Biotechnology Journal.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.